Eli Lilly and Company (LLY)
Will Eli Lilly Do a Stock Split in 2024?
Eli Lilly's surging valuation has made the case for a stock split. Many growth stocks have deployed stock splits in recent years, including Eli Lilly rival Novo Nordisk.
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Eli Lilly (LLY) concluded the recent trading session at $941.60, signifying a -0.93% move from its prior day's close.
3 Biotech Stocks to Buy in Case of Another Pandemic
While the last two major global pandemics were more than 100 years apart, a few international agencies warn of the increased potential for more frequent pandemics. This is admittedly a concerning and uncomfortable thought, considering the severe societal damage that occurred as a result of the Covid-19 pandemic.
4 Large Drug Stocks to Watch as Innovation, M&A Pick Up
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co LLY and maintained a price target of $885.
2 Unstoppable Growth Stocks to Buy and Hold for the Next Decade
Eli Lilly's blockbuster new weight-loss treatment is helping to drive a $130 billion anti-obesity market. Electric vehicles, self-driving taxis, and humanoid robots give Tesla's shareholders multiple ways to win.
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Many top companies have announced stock splits this year after their shares surged in recent times. These operations lower the price of each individual share, making the stock more accessible for a broader range of investors.
Is Eli Lilly a Good Dividend Stock to Buy Now?
Eli Lilly stock has soared, but investment bank analysts who follow the drugmaker think it can climb higher. According to electronic health records, Eli Lilly's drug for chronic weight management is outperforming the competition.
This 1 Piece of Bad News for Novo Nordisk Is Good News for Eli Lilly Stock
Researchers compared the effectiveness of Novo Nordisk and Eli Lilly's weight loss drugs. Patients stopped treatment with both at high rates.
Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.
The Food and Drug Administration recently approved Kisunla as a treatment for early symptomatic Alzheimer's disease. Despite the news, shares of Eli Lilly didn't take off.
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
Eli Lilly and Novo Nordisk compete in the diabetes and obesity care markets. Outside of weight loss, Lilly also has a strong portfolio of medicines used in cancer, plaque psoriasis, and more.
Should You Buy Eli Lilly Stock After Another Major Win?
Eli Lilly has earned approval for an Alzheimer's disease therapy. It's yet another blockbuster drug for its lineup.
